The crystal structure of Leishmania donovani tyrosyl-tRNA synthetase (LdTyrRS) in complex with a nanobody and the tyrosyl adenylate analog TyrSA was determined at 2.75 Å resolution. Nanobodies are the variable domains of camelid heavy chain-only antibodies. The nanobody makes numerous crystal contacts and in addition reduces the flexibility of a loop of LdTyrRS. TyrSA is engaged in many interactions with active site residues occupying the tyrosine and adenine binding pockets. The LdTyrRS polypeptide chain consists of two pseudo-monomers, each consisting of two domains. Comparing the two independent chains in the asymmetric unit reveals that the two pseudo-monomers of LdTyrRS can bend with respect to each other essentially as rigid bodies. This flexibility might be useful in the positioning of tRNA for catalysis since both pseudo-monomers in the LdTyrRS chain are needed for charging tRNA Tyr . An "extra pocket" (EP) appears to be present near the adenine binding region of LdTyrRS. Since this pocket is absent in the two human homologous enzymes, the EP provides interesting opportunities for obtaining selective drugs for treating infections caused by L. donovani, a unicellular parasite causing visceral leishmaniasis, or kala azar, which claims 20,000 to 30,000 deaths per year. Sequence and structural comparisons indicate that the EP is a characteristic which also occurs in the active site of several other important pathogenic protozoa. Therefore, the structure of LdTyrRS could inspire the design of compounds useful for treating several different parasitic diseases.
Introduction
The leishmaniases are a variety of diseases caused by more than 20 Leishmania species. These protozoans are transmitted through the bites of infected female phlebotomine sandflies. Approximately 350 million people in the tropics and sub-tropics are at risk of infection, with 0.9e1.3 million new cases and 20,000 to 30,000 deaths annually [1, 2] . Depending on the species involved, cutaneous, mucocutaneous or visceral leishmaniasis can develop, the latter being the most serious as far as number of deaths is concerned. Caused by L. donovani and L. infantum, visceral leishmaniasis (VL), or kala-azar, is fatal if left untreated in 95% of the cases. VL is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anemia. About 200,000 to 400,000 new cases of VL occur each year and children are the most severely affected group [2, 3] . Available drugs used for the treatment of the leishmaniases are mainly pentavalent antimonial complexes, amphotericin B, the aminoglycoside paromomycin, and the alkylphosphocholine miltefosine, either as single or combination treatments [4, 5] . Most of the available drugs are not oral and, due to their complicated administration regimens, low efficacy for parasite elimination, poor safety profile, occurrence of drug resistance [4] and treatment failure, there is an urgent need to take new oral drug candidates into clinical development [1] .
Protein translation is an essential cellular function in Trypanosomatid parasites. The overall fidelity of protein synthesis relies on the accuracy of both codon-anticodon recognition and aminoacyltRNA synthesis [6] . Aminoacyl-tRNA synthetases (aaRSs) play a crucial role in accurately pairing each amino acid with its cognate tRNA through a two-step esterification reaction forming aminoacyl-tRNA [7] . The first, ATP dependent, step leads to the formation of an enzyme-bound aminoacyl-adenylate and an inorganic pyrophosphate leaving group. The second step results in the 3'-esterification of the tRNA with the amino acid moiety and generation of AMP as a leaving group, followed by product release [6] .
Human cells have two sets of aaRS, one for cytosolic aminoacyltRNA synthesis and a second one, of bacterial evolutionary origin, for aminoacylation of mitochondrial tRNAs. In contrast, Trypanosomatids contain only a single set of aaRS genes, with the exception of three amino acids (aspartate, lysine and tryptophan) for which two aaRS genes exist [8] . Hence, in these parasites 17 aaRSs have to function in both subcellular locations. This is a remarkable difference between human and parasite aaRS. It suggests that inhibiting any of these aaRS in parasites would have the effect of hindering protein synthesis in the cytosol as well as in the mitochondria.
AaRSs have been recognized as validated antimicrobial drug targets [9e11] . Anti-aaRS compounds can act by blocking the binding site of ATP and/or amino acid, an allosteric site, tRNA recognition, or a secondary editing site [12] . Successes in targeting pathogenic aaRS are encouraging. At least two drugs, mupirocin and tavaborole, are in clinical topical use against, respectively, Staphylococcus aureus infections and onychomycosis. Mupirocin binds both the ATP and Ile binding sites of S. aureus isoleucyl-tRNA synthetase (IleRS), while tavaborole (Kerydin™) inhibits fungal leucyl-tRNA (LeuRS) by binding to its editing site [10, 13, 14] . Compounds targeting parasitic protozoan aaRS have been shown to interfere with protozoan cell growth [10, 15] . Also, several natural products inhibit aaRS from important tropical parasites. For instance, Plasmodium falciparum prolyl-tRNA synthetase, lysyltRNA synthetase and threonyl-tRNA synthetase are inhibited by the natural products halofuginone, cladosporin and borrelidin, respectively [12, 16, 17] . These compounds have also inhibitory effects on malaria parasite growth in vitro or in vivo [18] . Here we focus on tyrosyl-tRNA synthetase (TyrRS) from L donovani.
TyrRS belongs to the class I aaRSs, characterized by a Rossmann fold and two hallmark sequence motifs ("HIGH" and "KMSKS"). More specifically, TyrRS belongs to subclass Ic, together with tryptophanyl-tRNA synthetase (TrpRS), and contains an "AIDQ" motif characteristic of the ATP binding site. Progress has been made in inhibiting bacterial TyrRSs both with compounds identified from natural sources, as is the case of SB-219383 [19e21] , and with synthetized inhibitors [22e25]. However, there have been no significant advances in experimental work with parasitic TyrRSs as drug targets [10] . A structure guided approach in the design of drugs for the treatment of VL would greatly benefit from the knowledge and analysis of new leishmanial TyrRSs structures, in particular from L. donovani and L. infantum.
Recent biochemical and parasitological studies on L. donovani TyrRS (LdTyrRS) have indicated that the enzyme has a cytoplasmic subcellular location and that, as expected, it is essential for cell proliferation. Interestingly, an intriguing additional function, i.e. an effect on inflammation, has been shown in L. donovani for secreted TyrRS. The enzyme appears to be involved in attracting neutrophils and binding to macrophages through an N-terminal ELR motif triggering further cytokine TNF-a and IL-6 release by host macrophages [26] . Regarding inhibition studies of LdTyrRS, the flavonoid fisetin has shown to have anti-leishmanial properties and its effect has been ascribed to its anti-TyrRS activity [26] . This inhibitory effect of fisetin agrees well with the observation that this compound binds to the active site of L. major TyrRS (LmTyrRS) [27] .
In order to provide a structural platform to assist further antileishmanial drug development, we report here the 2.75 Å resolution crystal structure of LdTyrRS in complex with the tyrosyl adenylate analog TyrSA (5 0 -O-[N-(L-tyrosyl)sulfamoyl]adenosine) and a specific anti-LdTyrRS nanobody (NbA) used as crystallization chaperone [28] . Nanobodies are the variable domains of camelid heavy chain-only antibodies which can substantially increase the success of protein crystal growth [28] . The structure of LdTyrRS in complex with TyrSA will in particular expand our insight into the binding characteristics of ligands in the neighborhood of the adenine binding pocket, a feature which was not probed in the previous structures of LmTyrRS. Analysis of the structure indicates the presence of promising opportunities to exploit structural differences of the parasite enzyme with both human cytosolic and mitochondrial TyrRS variants. Of particular relevance is the presence of an "extra pocket" (EP) near the adenine binding site in the structure of LdTyrRS. This pocket is absent in the two human homologs and hence provides distinct opportunities to arrive at selective inhibitors. The EP is also present in the structure of L. major TyrRS [27] , and, in view of the considerable similarities in the active site regions, is highly likely to occur in other Leishmania species causing human disease. The same holds for TyrRS from related Trypanosomatids, such as Trypanosoma brucei, the causative agent of human African trypanosomiasis, and T. cruzi, responsible for Chagas disease. In addition, TyrRS from the malaria parasite Plasmodium falciparum [29] appears to contain a close variant of the EP. Amino acid sequence comparisons suggest that the EP occurs in even more parasitic protozoa. Hence the EP may allow the development of selective tyrosyl-tRNA synthetase inhibitors which could become new tools in tackling several major diseases caused by unicellular parasites.
Materials and methods

LdTyrRS expression and purification
LdTyrRS was cloned into the AVA0421 vector and expressed in E. coli for subsequent purification. A first round of Ni-NTA affinity chromatography was followed by cleavage of the N-terminal His 6 -tag using 3C protease (overnight at 4 C). In a second Ni-NTA step, the cleaved LdTyrRS was purified from the N-terminally His 6 -tagged 3C protease. A size-exclusion chromatography on a Superdex 200 column (Amersham Pharmacia Biotech) using SEC buffer (25 mM HEPES at pH 7.25, 500 mM NaCl, 2 mM TCEP, 5% glycerol, 0.025% NaN 3 ) was performed and a final yield of 6 mg of pure LdTyrRS per liter of E. coli culture was obtained and concentrated to above 15 mg/mL for co-crystallization with NbA.
NbA production
LdTyrRS specific nanobodies were generated as previously described [28] . In brief, one llama (Lama glama) was immunized six times with in total 0.9 mg of LdTyrRS. Four days after the final boost, blood was taken to isolate peripheral blood lymphocytes. RNA was purified from these lymphocytes and reverse transcribed by PCR to obtain cDNA. The resulting library was cloned into the phage display vector pMESy4 bearing a C-terminal hexa-His tag and a CaptureSelect sequence tag (Glu-Pro-Glu-Ala). Six different families were selected by biopanning. For this, LdTyrRS was solid phase coated directly on plates, LdTyrRS specific phage were recovered by limited trypsinization. After two rounds of selection, periplasmic extracts were made and subjected to ELISA screens [28] .
NbA expression and purification
NbA cloned in the pMESy4 vector that carries the pelB sequence coding for the secretion signal peptide of PelB was expressed in E. coli for subsequent purification from the bacterial periplasm. NbA purification was performed as previously described by Pardon et al. [28] . Briefly, after induction, the bacterial pellet was gently resuspended in TES buffer (200 mM Tris at pH 8.0, 0.5 mM EDTA, 500 mM Sucrose) and upon incubation on ice the periplasmic content was recovered by centrifugation after an osmotic shock with ice-cold 50 mM Tris at pH 8.0, 0.125 mM EDTA, 125 mM Sucrose. NbA was purified from the periplasmic content by Ni-NTA affinity chromatography followed by size-exclusion chromatography on a Superdex 75 column (Amersham Pharmacia Biotech) using NbSEC buffer (25 mM HEPES at pH 7.25, 300 mM NaCl, 1 mM TCEP, 10% glycerol, 0.025% NaN 3 ) and concentrated to above 10 mg/ mL for co-crystallization with LdTyrRS.
Nanobody-LdTyrRS binding studies
Nanobody (Nb) binding studies were systematically carried out by native gel electrophoresis and size-exclusion chromatography for eight nanobodies. The purified Nb was first incubated with LdTyrRS for 30 min at 4 C and after native gel electrophoresis the positions of LdTyrRS, Nb and complex were analyzed. The formation of the complex was also tested by comparing the elution peaks on a Superdex 200 column (Amersham Pharmacia Biotech) where LdTyrRS was run as well as the potential LdTyrRSNb complex formed upon 30 min incubation at 4 C.
LdTyrRS aminoacylation assay
The IC 50 of TyrSA in the LdTyrRS aminoacylation assay was determined using methods as previously described [30e32] . Briefly, TyrSA (tested in triplicate) was pre-incubated for 15 min at room temperature with 0.13 nM LdTyrRS, 500 nM [3H]L-tyrosine (40 Ci/mmol), 0.2 mM ATP, 0.1 U/mL pyrophosphatase, 0.2 mM spermine, 0.2 mg/mL bovine serum albumin, 2.5 mM dithiothreitol, 1 mM MgCl 2 , 25 mM KCl, 50 mM HEPES-KOH pH 7.6, and 2% DMSO.
The reactions were started with 200 mg/mL tRNA from brewer's yeast (Roche) and incubated for 30 min at room temperature without shaking. The reactions were stopped with cold 10% trichloroacetic acid and processed as previous described [32] .
LdTyrRSNbATyrSA complex crystallization
Purified LdTyrRS and NbA proteins were incubated on ice for 30 min at a 1:2 M ratio followed by buffer exchange to crystallization buffer (25 mM HEPES at pH 7.25, 100 mM NaCl, 1 mM TCEPHCl, 5% glycerol, 0.025% NaN 3 ). The complex (5 mg/mL) was then incubated with 200 mM of TyrSA (
adenosine) on ice for 30e60 min prior to setting up the crystallization tray. The crystals were obtained after 5e7 days at room temperature by vapor diffusion using sitting drops equilibrated against a reservoir containing 0.1 M sodium cacodylate pH 5.7, 22% PEG 4000. The drops contained 1 mL of LdTyrRSNbATyrSA complex at 5 mg/mL and 1 mL of reservoir solution. After growth, crystals were flash frozen in liquid nitrogen in cryo-solution (25% glycerol in reservoir solution) and stored until data collection.
Data collection and structure determination
Data was collected under cryogenic conditions at the Stanford Synchrotron Radiation Lightsource (SSRL) using beamline 12-2 at a wavelength of 1 Å. Data processing was carried out with the program HKL2000 [33] . Initial phases were obtained by molecular replacement using Phaser [34] with as models the structure of L. major TyrRSTyrosinol ( [27] ; PDB: 3P0J) and a NbA homology model generated by Phyre2 [35] . This was followed by iterations of manual building and rebuilding using Coot [36] alternated with refinement of the structure with REFMAC5 [37] . Refinement restraints for TyrSA were obtained with the Grade web server [38] . The structure validation server MolProbity [39] was used throughout the process for structure validation. The final data collection and crystallographic refinement statistics are given in Table 1 . Pymol [40] was used to create the figures. Coordinates and structure factors of the LdTyrRSNbATyrSA complex have been deposited in the Protein Data Bank under the PDB ID: 5USF.
Results
Leishmania donovani tyrosyl-tRNA synthetase structure
The crystal structure of the LdTyrRSNbATyrSA complex was determined at a resolution of 2.75 Å (Table 1) , where NbA is a nanobody to be described below, TyrSA a tyrosyl adenylate analog, and the symbol "" indicates a non-covalent complex. The crystals contain two copies of the LdTyrRSNbATyrSA complex in the asymmetric unit (ASU). Each LdTyrRS molecule is bound to one NbA molecule (Fig. 1) . Canonical TyrRSs are formed by two identical monomers, each consisting of a catalytic domain (CD) and an anticodon binding domain (ABD). Instead, the 75 kDa LdTyrRS chain is a pseudo-dimer where the structurally similar N-and Cterminal pseudo-monomers share only 23% sequence identity. As described for LmTyrRS [27] , the N-and C-terminal pseudomonomers are connected by a flexible linker between a14 and b9 (Fig. 1A) (Fig. 1B ). These motifs have been shown to be involved in the catalytic activity of TyrRS enzymes [27, 41] . The motifs are absent in the C-terminal pseudo-monomer, suggesting that this half of the molecule is not able to perform amino acid activation. This is in agreement with the observations that TyrSA is bound to the active site in the N-terminal CD of LdTyrRS, but not to the C-terminal CD. Hence, the N-terminal CD is called the "functional CD" and the C-terminal CD the "nonfunctional CD" (Fig. 1A) . involved in the recognition of the tRNA anticodon arm, as described for LmTyrRS [27] , the loop located between b7 and b8 in the Nterminal ABD is considerably shorter than the corresponding loop between b14 and b15 in the C-terminal pseudo-monomer. This loop is responsible for binding the anticodon base G34 of tRNA Tyr according to the structure of Saccharomyces cerevisiae TyrRS [42] . The short b7-b8 loop in the N-terminal ABD homolog is unable to engage with this base (Fig. 1C) . Therefore, the N-terminal ABD of LdTyrRS is called the "non-functional ABD" and the C-terminal ABD the "functional ABD" (Fig. 1A, C) . The superposition of the two LdTyrRS chains A and B in the LdTyrRSNbATyrSA crystals yields an overall r.m.s.d of 1.57 Å for 678 C a atoms. All four individual domains of the two chains in the asymmetric unit are highly similar, with r.m.s.d values ranging between 0.25 and 0.77 Å. The N-or C-terminal pseudo-monomers A) The LdTyrRS pseudo-dimer structure in complex with nanobody A (pink) and the tyrosyl adenylate analog TyrSA (CPK model). The N-terminal functional catalytic domain (CD) is shown in dark orange, the C-terminal nonfunctional CD in light orange, the N-terminal non-functional ABD in light blue, the C-terminal functional ABD in dark blue. The linker connecting the N-terminal and C-terminal pseudo-monomers of LdTyrRS is shown in dark green, while the plant/plastid insertion present in Trypanosomatid TyrRSs, described previously by Larson et al. [27] , in the N-terminal ABD is shown in bright green. The ELR motif is located in the exposed a2 in the functional CD. B) Domain organization of TyrRS from L. donovani, L. major, P. falciparum (PfTyrRS), human (HsTyrRS) and yeast S. cerevisiae (ScTyrRS). Domain colors correspond to the ones in the LdTyrRS structure in part A. The characteristic motifs HIGH, AIDQ and KMSKS in the functional catalytic domain as well as AC1 and AC2 in the nonfunctional and functional anticodon binding domains are depicted. When processed by an elastase enzyme HsTyrRS gives rise to an N-terminal TyrRS known as Mini TyrRS and a C-terminal EMAPII-like domain (yellow), which has cell signaling activity [29] . focus our structural analysis on chain A of LdTyrRS. The KMSKS loop adopts a closed conformation in our LdTyrRS structure with the tyrosyl adenylate analog TyrSA bound (Fig. 3) . Interestingly, the KMSKS loop was also found in a closed conformation in LmTyrRS, even in the absence of ATP or tyrosyl adenylate analogs [27] . Not only the KMSKS loop can have an open and closed conformation, also the entire active site can be in an open or closed state. These two distinct conformational states have been described by Larson et al. [27] for the active site in the LmTyrRSTyrosinol and LmTyrRSFisetin crystal structures. In the functional catalytic domains of LdTyrRSTyrSA both chains adopt the closed state (Fig. 3) . In this state, the loop containing residues 146e154 is well-ordered and reaches the proximity of the sulfamoyl group of TyrSA, where the phosphate of tyrosyl adenylate or the a and b phosphates of ATP would be during the catalytic reaction by TyrRS. As in the LmTyrRS closed state, the LdTyrRS a4 and the loop connecting this helix with a5 curl over the active site to interact with residues 40e43 preceding the HIGH motif ( 47 HIAQ 49 in LdTyrRS) involved in the enzyme's catalytic activity (Fig. 3) .
NbA structure and its interactions with LdTyrRS
After various failed attempts to crystallize LdTyrRS, we hypothesized that some flexibility in the four-domain pseudo-dimer was impairing crystal formation. With the use of nanobodies as crystallization chaperones we aimed to freeze LdTyrRS in a conformation more amenable for crystal growth, while the nanobody might also be able to establish favorable crystal contacts. Nanobodies are small compact single-domain fragments of the original heavy-chain camelid antibodies that retain their full antigen-binding capacity. Typically three variable loops of bstrands, referred to as the complementarity determining regions (CDRs), are responsible for binding to the antigen. The usually long CDR3 loop of nanobodies can have a special significance since cryptic epitopes located in cavities or clefts of the antigenic protein are sometimes recognized by it [28] . However, in the LdTyrRSNbATyrSA complex the CDR3 loop in anti-LdTyrRS llama nanobody A (NbA) does not interact extensively with LdTyrRS as described below.
We tested 4 anti-LdTyrRS nanobodies as crystallization chaperones before obtaining high quality LdTyrRS crystals with NbA. The presence of the tyrosyl adenylate analog TyrSA was essential as well, and its interaction with the enzyme will be described later. The 1:1 LdTyrRSNbA complex was purified by size exclusion chromatography (SEC) and the binding of NbA to LdTyrRS was verified through the shift of the 280 nm absorbance elution peak (Fig. 4A) , corroborating the formation of a larger molecular weight species. The presence of both proteins LdTyrRS and NbA in the larger molecular weight species was confirmed by SDS-PAGE (Fig. 4B ). In addition, native gel binding assays were performed supporting the interaction between the two proteins (not shown).
NbA is a 14 kDa protein and consists of two b-sheets with a Greek key topology (Fig. 4C) G is À8 kcal/mol (calculated by PISA). The contacts between the variable region of NbA and LdTyrRS are predominantly hydrophilic (Fig. 4D) . Residues N31 and W33 of CDR1, residues R50 and G54 of CDR2, and, residue R102 of CDR3 (through a water molecule), make hydrogen bonds with LdTyrRS. Side chain carbon atoms of residues N56 (CDR2) and Y103 (CDR3) are engaged in hydrophobic interactions with the enzyme. In addition, several frame work residues, not located in CDR loops, establish polar (R19, S69 and S71) and hydrophobic (Y80) interactions with the synthetase.
It is of interest to see if NbA has a stabilizing effect on LdTyrRS, thereby promoting possibly crystal growth. The comparison with the LmTyrRS structure is helpful here. The loop 541e571 connecting the non-functional CD with the functional ABD in LdTyrRS interacts with NbA and exhibits a well-defined density, but the equivalent loop in the three LmTyrRS crystal structures available is half or completely disordered [27] . Hence, it seems reasonable to conclude that NbA diminishes the flexibility of an exposed loop in LdTyrRS.
A second reason why nanobodies can promote crystal growth is by generating additional crystal contacts. In the LdTyrRSNbATyrSA complex, NbA bound to chain A establishes crystallographic interactions with the other LdTyrRS copy (Chain B) with a BSA of 792 Å 2 . Moreover, NbA also contacts a symmetry-related
NbA copy with a BSA of 969 Å 2 . The nanobody is clearly engaged in extensive interactions with various protein chains in the crystal. Most likely NbA increases the probability of crystal growth by making numerous crystal contacts and by diminishing the flexibility of an exposed loop.
TyrSA binds to LdTyrRS with its adenine ring near an extra pocket (EP)
The tyrosyl adenylate analog TyrSA ( (Fig. 5A ) was necessary for obtaining well diffracting LdTyrRS crystals. As measured by aminoacylation assays, TyrSA binds tightly to LdTyrRS with an IC 50 of 0.69 nM. The inhibitor was found to occupy the active site of the functional CD (Fig. 5B ) in both LdTyrRS chains in the asymmetric unit. The high affinity of the compound for the enzyme is most probably explained by the large number of interactions with LdTyrRS active site residues, limiting thereby the flexibility of this region. This decrease in motility is likely responsible for the fact that TyrSA was crucial for obtaining well diffracting crystals of the LdTyrRSNbA complex.
The LdTyrRS active site contains two critical pockets: the tyrosine binding pocket (YBP) where the tyrosyl group of TyrSA is situated, and the adenine binding pocket (ABP) where the adenine moiety of TyrSA binds (Fig. 5C) . As evidenced through the use of PoseView as part of the ProteinPlus structure-based modelling software tools [44, 45] , the tyrosyl adenylate analog contacts many LdTyrRS active site residues (BSA of 933 Å 2 ), mainly through hydrogen bonds, although a few hydrophobic interactions are present as well. Residues making hydrogen bonds with the TyrSA tyrosyl group in the YBP are Y36, Y163, Q167, D170 and Q185. Residues G38, A72 and F75 are responsible for the hydrophobic interactions between enzyme and tyrosine moiety in the YBP. A hydrogen bond is established between an oxygen atom belonging to the sulfamoyl group of TyrSA and the main chain nitrogen atom of residue E40 of LdTyrRS. The residues responsible for hydrogen bond interactions with the ribose ring are D37, G182 and D184. In the ABP, hydrogen bonds with the adenine moiety are made by H210 and L213, while M212 makes hydrophobic contacts with the adenine ring.
Further analysis of the active site near the ABP showed a previously not reported feature: a pocket in LdTyrRS close to the TyrSA adenine moiety (Fig. 6 ). This pocket, called "extra pocket" (EP), which is also present in the L. major TyrRS structure, is mainly lined by residues belonging to helix a3 as well as by the side chain of residue H210. Helix a3 atoms contributing to the pocket (Fig. 6) are 
The extra pocket (EP) of LdTyrRS is absent in the human TyrRS enzymes
In order to discover new opportunities for drug design, the active sites of LdTyrRS and the two HsTyrRS enzymes were compared ( Fig. 7 ; for a list of TyrRS structures compared with LdTyrRS in this paper see Table 2 ). While the YBPs are highly similar among the compared TyrRS structures, the analysis of the ABP reveals interesting amino acid differences between human and parasite enzymes as also described by Larson et al. [27] on the basis of the comparison of their L. major TyrRS structure with the two human TyrRS enzymes. The basic conclusions of these authors are confirmed by our current LdTyrRS structure.
Interestingly, the EP offers additional exploitable differences between the enzymes from parasite and host. When superimposing the L. donovani and human TyrRS structures, a substantial difference in position of a3 in the human enzymes vs. parasite enzyme is evident (Figs. 7 and 8) . Specifically, in cytosolic HsTyrRS, the helix corresponding to the LdTyrRS a3 helix is moved 3.0 Å towards the EP of LdTyrRS (Fig. 8B) , while in the mitochondrial HsTyrRS structure this helix is moved by 4.6 Å towards the EP of LdTyrRS (Fig. 8C, D) . As result of this shift, the EP is absent in the human enzymes.
It is worthwhile to try to discern why the EP is absent in the human enzymes. It appears that helix a3 side chains forming the EP in LdTyrRS are all different in the human enzymes. For instance, Q49 of LdTyrRS is equivalent to Y52 and H91 in the human cytosolic and mitochondrial enzymes, F52 of LdTyrRS to V54 and L93 in these two human homologs, K53 of LdTyrRS to P55 and A94, and N56 of LdTyrRS to K58 and G97, respectively. Actually, the L. donovani
TyrRS residues from C35 to K59, comprising helix a3, and the L. donovani TyrRS residues V206 to L213, surrounding LdTyrRS H210, are essentially all different when comparing LdTyrRS to the two human TyrRS enzymes (Fig. 9) . As a result of all these changes, helix a3 shifts in the human enzymes compared to the L. donovani enzyme, and the EP is absent in the human homologs (Fig. 7) . 
A sequence fingerprint for the extra pocket (EP)
The seven residues forming the EP in LdTyrRS: D37, A48, Q49, F52, K53, N56 and H210 can be used as an "EP fingerprint": D-x 10 -AQ-x 2 -FK-x 2 -N-z-H, where x stands for any amino acid and z for a variable large number of residues. This EP fingerprint is present in the TyrRS sequences of all Leishmania species analyzed (Fig. 9) . Hence, it is likely that the EP is present in all Leishmania TyrRS enzymes, as confirmed by a comparison of the L. major and L. donovani TyrRS structures (Fig. 7A and B) . The EP fingerprint also occurs in other Trypanosomatids. The latter include the important human pathogens Trypanosoma brucei and T. cruzi, as well as T. vivax, causing nagana in cattle in sub-Saharan Africa. Given the absence of the EP in the two human homologs, this difference indicates interesting opportunities for arriving at compounds with higher affinity for Trypanosomatid than for the human tyrosyltRNA synthetases.
Discussion
The structure of the 75 kDa LdTyrRS in complex with TyrSA has increased our insights in the architecture of this unusual member of the tRNA synthetase family. The two pseudo-monomers comprise each two domains. The N-terminal pseudo-monomer contains a functional catalytic domain and a non-functional anticodon-binding domain, and the C-terminal pseudo-monomer a non-functional catalytic domain and a functional anticodon binding domain. A similar architecture had been observed for L. major TyrRS [27] . Comparison of the two crystallographically independent chains in our structure showed that the two pseudo-monomers can flex with respect to each other. This results in a considerable difference in position of the functional anti-codon binding domain at the Cterminus of the second pseudo-monomer when the N-terminal pseudo-monomers are superimposed (Fig. 2) . This flexibility might be essential in positioning tRNA
Tyr properly with respect to the catalytic domain during the second catalytic step of the reaction Full length [49] catalyzed by Leishmania TyrRS. The binding mode of TyrSA to LdTyrRS provides additional insight as to how the tyrosyl-adenylate adduct binds to the active site of this group of TyrRS enzymes. A new feature revealed by our analysis of the LdTyrRS structure is the presence of an "extra pocket" (EP), close to the adenine binding pocket and filled by three mutually interacting water molecules. This EP is present as well in the L. major TyrRS structure [27] and, based on amino acid sequence comparisons, also in other Trypanosomatids. Several of the latter, such a T. brucei and T. cruzi, are major global human pathogens causing death and disease in particular in low-income countries [2, 3] . Since the EP is absent in the two human TyrRS enzymes, this difference between enzymes from parasite and human host indicates opportunities to arrive at inhibitors with high affinity and selectivity. It is of interest to evaluate if the EP is present in the TyrRS from other medically important parasites. The enzyme from the protozoan Plasmodium falciparum, the major causative agent of malaria, has been the subject of several studies, including the determination of the crystal structure of cytosolic P. falciparum TyrRS (PfTyrRS) [29] . The EP fingerprint is present in PfTyrRS with two changes: the F at the fourth position in the fingerprint is in PfTyrRS an L, which conserves the hydrophobic side chain characteristic at this position, and the N at the sixth position is an I in PfTyrRS (Fig. 9) . A comparison of the structure of LdTyrRS with the crystal structure of P. falciparum TyrRS [29] , reveals that in the latter enzyme the EP is indeed present (Fig. 10) . In this case, the EP harbors only one deep water molecule, the equivalent of Wat2 in the LdTyrRS EP. The absence of Wat1 is due to the fact that residue N56, in the back of the EP of LdTyrRS (Fig. 7B) , is substituted by I80 in the P. falciparum enzyme, providing a more hydrophobic environment within the pocket and no hydrogen-bonding partner for Wat1. Based on the amino acid sequence alignment (Fig. 9) , this same feature is present in P. vivax, another important malaria parasite. These comparisons suggest that there are opportunities to arrive at high affinity PfTyrRS inhibitors with good selectivity. This is extra interesting since Kahn [18] has recently emphasized the opportunities of TyrRS as a drug target for malaria.
Turning to other protozoa causing considerable human suffering and death across the globe, the comparison of EP fingerprints in Cryptosporidium parvum, Toxoplasma gondii and Giardia lamblia reveals that in these pathogens there is only a single residue difference in the fingerprint: the F at the fourth position is an L, I or A in these three parasites, respectively. Hence the EP in these protozoa is even closer to that of LdTyrRS than the EP in the two P. falciparum species. The N at the sixth position of the fingerprint is maintained so that it is very likely that in these three species the EP is present with Wat1 deep in the pocket. Consequently, the EP might enable the development of effective and selective TyrRS inhibitors for treating cryptosporidiosis, toxoplasmosis and giardiasis. Although in Entamoeba histolytica the EP fingerprint is less perfectly conserved, with differences in the first (D to N), fourth (F to L) and fifth (K to T) positions with respect to LdTyrRS, two of these three side chain changes are very conservative. Hence, an exploitable EP might also exist in the TyrRS of this pathogen.
Conclusions
The structure of the LdTyrRSNbATyrSA complex elucidated revealed different mutual orientations of its two pseudo- Fig. 10 . P. falciparum TyrRS residues forming the extra pocket (EP). Surface representation of the EP in the PfTyrRSTyrAMP crystal structure [29] (PDB: 3VGJ). Protein carbon atoms are colored grey, nitrogens blue, oxygens red and phosphorous orange. All but two (L76 and I80) of the residues involved in the EP formation are shared with trypanosomatids. PfTyrRS harbors one deep water in the EP (equivalent to Wat2 in LdTyrRS) and a water molecule at the EP entrance (equivalent to Wat3 in LdTyrRS), shown as red spheres. TyrAMP carbon atoms are shown in green.
monomers. The comparison of the LdTyrRS structure to both human homologs showed major differences compared in the active site, in particular the presence of an "extra pocket" in the parasite enzyme. The latter feature is also found in the TyrRSs from other unicellular parasites and could be a key element in the development of novel compounds for treating diseases caused by a wide range of important pathogenic protozoa.
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